Erlonat 150 mg

Erlotinib belongs to a class of medications known as tyrosine kinase inhibitors, specifically targeting the epidermal growth factor receptor (EGFR), a protein that can drive uncontrolled cell growth when mutated. By blocking this receptor's activity, Erlotinib helps slow or stop the growth and spread of cancer cells that rely on this particular pathway. It is commonly used to treat non-small cell lung cancer, particularly in patients whose tumors have specific EGFR gene mutations, identified through genetic testing to help determine if this targeted approach is likely to be effective. Erlotinib is also used in combination with other treatments for advanced pancreatic cancer, expanding its role across different cancer types. This precision approach allows treatment to be tailored to the specific characteristics of an individual's cancer, often providing meaningful benefit for patients with these particular genetic markers. As an oral targeted therapy, Erlotinib offers a convenient treatment option, allowing much of the treatment to take place at home between clinical check-ins. It is typically taken once daily on an empty stomach, following a schedule established by an oncologist based on the patient's specific cancer characteristics and treatment plan. Regular monitoring, including imaging studies and periodic check-ins, helps track treatment response and guide any necessary adjustments. As with all targeted cancer therapies, Erlotinib should be used strictly under the guidance of an experienced oncology healthcare provider.